Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0S0FD
|
|||
| Drug Name |
E2027
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Lewy body dementia [ICD-11: 6D82] | Phase 2 | [1] | |
| Parkinson disease [ICD-11: 8A00.0; ICD-10: F02.3, G20; ICD-9: 332] | Phase 2 | [1] | ||
| Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 1 | [2], [3] | ||
| Company |
Eisai
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Phosphodiesterase 9 (PDE9) | Target Info | Antagonist | [2], [3] |
| KEGG Pathway | Purine metabolism | |||
| Pathway Interaction Database | Regulation of Androgen receptor activity | |||
| Reactome | cGMP effects | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04764669) A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid Copathology. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.